Reprinted with permission from World, Large, a news website on nature, science, health, politics and travel.
In another study on the use of psychedelic compounds as a drug, two doses of psilocybin – a compound that “magic mushrooms” give their magic – significantly reduced major depressive symptoms in adults when combined with adjuvant psychotherapy.
The small study included 24 adults with two hours of psilocybin therapy sessions and 24 weeks of follow-up, and shocked researchers at the Johns Jopp Hawkins School of Medicine’s Center for Psychiatric and Consciousness Research (CPCR).
Alan Davis, a professor of psychiatry and behavioral sciences, says, “Clinical trials have seen a four-fold greater impact on the market than conventional antidepressants.”
According to data from the US Centers for Disease Control (CDC), millions of adults suffer from chronic anxiety disorder at some point in their lives. One in 6 will have symptoms of depression during some period of their life.
In this new trial, the researchers looked at whether psilocybin (already given as a ‘breakthrough status’ treatment for depressive disorder) could be effective enough to be used as a standard depressive disorder treatment.
Instead of targeting the “reactive” type of discomfort or frustration caused by traumatic experiences, his team was urged by public health officials to explore the effects of psilocybin in an extended population for people with long-term, persistent, and less defined major depressive disorder. , Because it has a more potential impact on public health.
Frustration in salvation
Director, Two Types of Land Griffiths Ph.D. “Because there are so many types of major depressive disorder that can affect how people react to treatment, I was surprised that most of our study participants found cilosibin treatment to be effective,” says CPCR and pioneer of psychedelic therapy research. Who released its results this week JAMA Psychiatry.
In the clinical trial, out of a group of 24 participants, 67% showed a more than 50% reduction in depressive symptoms at one-week follow-up and a 71% reduction at four-week follow-up. Overall, four weeks after treatment, 54% of the participants were excused, meaning they no longer deserved to be indifferent.
The researchers say they will follow participants for a year after the study to see how long the antidepressant effects of suppository treatment last, and will report their findings in a later publication.
Check out: Magnetic brain treatment was found to relieve depression in 90% of participants with no negative side effects
“Because most other depressants take weeks or months to treat and can have unintended side effects, these findings could be a game changer if placed in future ‘gold-standard’ placebo-controlled clinical trials.
Become more mainstream
After working at Johns Hopkins since 2003, Roland Griffiths’ psychedelic experiments were first viewed with suspicion, but under his leadership the CPCRA has now completed many tests and studies of psychedelic compounds, such as:
As a result of his work, U.S. The Food and Drug Administration designates other compounds, such as the chemical type of ketamine, as ‘breakthrough therapy’, which was approved in the form of a nasal spray used to treat depression in the P. te people of Virginia.
MDMA also won the status of ‘Breakthrough Therapy’ from the FDA in 2017 after research proved its “surprising” success in sending an apology to PTSD.
Meanwhile, his position as one Illegal Medication varies. On Tuesday, reg Reagan state voters passed its first step to formally legalize the legal cessation of silosibin mushrooms, with the state establishing and regulating a program in which adults can and do use it. And, Washington DC voters have approved a measure that would effectively decriminalize “magic mushrooms” and other organic psychedelic drugs.
Send this research to friends by sharing it on social media
More: Can Mild ‘Depression’ Be Good For You? An enlightened look at the ‘epidemic’
